C-265At consideration in committee in the House of CommonsPrivate Member’s Bill
An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access)
Sponsor:
Marcus Powlowski, Member of Parliament (Thunder Bay—Rainy River)
Proposed changes
This enactment amends the Food and Drugs Act to establish a list of therapeutic products pre-approved for special access to allow streamlined access to treatment for patients with serious or life-threatening conditions or where there is an unmet need. It also provides parameters to guide the Minister of Health in issuing letters of authorization for the sale of new drugs for emergency treatment under the Food and Drug Regulations .
The path to law
Every bill has to clear each step, in both chambers. Tap a step's name to learn what it means.
· House of Commons
Completed.
March 11, 2026
· House of Commons
Completed.
June 10, 2026
· House of CommonsNext up
Current step.
· House of Commons
Not reached yet.
Not reached yet
· Senate
Not reached yet.
Not reached yet
· Senate
Not reached yet.
Not reached yet
· Senate
Not reached yet.
Not reached yet
· Senate
Not reached yet.
Not reached yet
· Governor General
Not reached yet.
Not reached yet
Committee study
After second reading, a examines the bill clause by clause.
“Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.”
“Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.”
“C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access). Discuss proposed amendments to the Food and Drugs Act related to…”
“C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access). Discuss proposed amendments to the Food and Drugs Act related to…”
“Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases.”
“…related to clinical trials and drug authorization specific to children, specifically Bill C 265: An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access).”
From the Commissioner of Lobbying. A bill is listed when the lobbyist's description makes clear it means this bill, not one with the same number from another Parliament.
What MPs said
The most recent recorded speeches on this bill. Links go to the official transcript of that sitting.